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number of incontinence and micturition episodes/day. Analyses of covariance 
were used to assess the effects of mirabegron on baseline-week 12 changes in 
WPAI. Longitudinal generalized estimating equations and Pearson correlation 
coefficients were used to assess associations between WPAI and OAB severity. 
Subgroup analyses were conducted for patients who discontinued prior OAB 
medication due to insufficient efficacy. RESULTS: Among the study sample (total 
N=858, employed N=394), mirabegron-treated patients experienced significantly 
greater improvement in TAI (12.3% vs. 6.7%, p<0.01) and greater but non-
significant improvements in absenteeism (0.2% vs. -0.5%), presenteeism (8.6% vs. 
6.0%), and TWPI (8.2% vs. 5.8%) than placebo-treated patients at week 12. . Based 
on the association analyses, 2.0%, 1.4% and 1.4% increases per additional 
incontinence episode and, 1.2%, 1.1% and 1.1% increases per additional 
micturition episode were observed in TAI, presenteeism, and TWPI respectively 
(p<0.01). Baseline-week 12 change in TAI was significantly correlated with 
changes in OAB severity (incontinence: r=0.17, micturition: r=0.11; p<0.01). 
Similar trends were observed in the patient-subgroup with prior treatment non-
response. CONCLUSIONS: Patients treated with mirabegron experience 
significantly reduced total activity impairment. Impairments in work 
productivity and activity outcomes are associated with OAB symptom severity, 
suggesting that treatments that improve symptom severity may also improve 
productivity impairment.  
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OBJECTIVES: Subjects with nocturia generally have a night-time overproduction 
of urine, i.e. problematic kidney function. The main manifestation is waking 
during the night to void (urinate). In people aged 40-64 years, the number of 
voids experienced per night correlated with increasingly poor sleep. A previous 
survey has shown that nocturia patients of working age have increased 
impairment in both work and non-work activities compared to subjects without 
nocturia. METHODS: Two clinical trials investigated the efficacy and safety of 
the orally disintegrating tablet desmopressin (Clintrials.gov – NCT01223937, 
NCT01262456). Subjects were females and males 19-87 years of age with nocturia 
(≥2 voids per night). The studies were conducted at primary and secondary care 
centers across the USA/Canada in 2010-2012. As part of the economic evaluation 
we collected work productivity data using the Work Productivity and Activity 
Impairment Questionnaire. RESULTS: There was a clear link between disease 
severity and productivity losses. For the full sample, the overall work 
productivity loss was 23.7%. Patients with on average less than 4 voids had an 
overall work productivity loss of 22.3%, which can be compared to 32.2% for 
patients with 4 voids or above per night. Impairment on free-time activities 
showed an even stronger impact from nocturia. The full sample presented an 
impairment of 33.7%. Patients with less than 4 voids presented a value of 32.9, 
whereas those with at least 4 voids per night presented an average impairment 
of 39.8%. The productivity reduction for subjects with at least 4 voids per night is 
at higher end when compared to productivity impairments for other chronic 
diseases. There also seems to be a linear relationship with number of voids per 
night. CONCLUSIONS: Nocturia has a profound effect on the quality of sleep and 
hence also productivity.  
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OBJECTIVES: Urinary symptoms can be managed with antimuscarinics  
(AMs) and alpha-blockers (αBs). There is currently limited real-life data on the 
pharmacological management of men with BPH. The objective was to evaluate 
treatment patterns for BPH patients with predominant urgency and frequency 
symptoms in UK primary care. METHODS: Observational study of men  
≥45 years whose recorded first diagnosis, symptom or therapy indicated BPH 
with predominant urgency and frequency between January 1, 2004 to September 
30, 2011 in THIN UK primary care data. Treatment patterns were evaluated, 
including switching (>1 different αBs/AMs) and discontinuation (no αB/AM 
prescriptions during the last six months), from start of symptoms/treatment  
to end of records/symptoms resolved. RESULTS: Of 8694 men identified  
(mean age 66.41 years, standard deviation 10.38), the majority (90.29%) received α 
B during follow-up (median two years). Of these, 81.82% were prescribed 
tamsulosin, 16.36% alfuzosin, 10.79% doxazosin, (<3% others). Proportion of α 
B discontinuation varied slightly between first-line αBs: tamsulosin 38.27% 
(N=6,033); alfuzosin 41.10% (N=876); doxazosin 36.08% (N=679). 1,160 (14.78%  
of αB-treated men) received αB and AM prescriptions within 30 days of each  
other. Of 2167 (24.93%) men receiving AM, 40.98% were prescribed  
tolterodine, 37.19% oxybutynin, 35.67% solifenacin, (<7% others). Proportion  
of AM switching and discontinuation varied between first-line AMs: tolterodine 
23.32% and 59.82% respectively (N=759); oxybutynin 24.60% and 54.70% (N=691);  
solifenacin 15.27% and 43.02% (N=537). Solifenacin had the highest average  
total duration of therapy, median 90 days (interquartile range [IQR] 30 to  
300), tolterodine 56 (IQR 28 to 224) and oxybutynin 56 (IQR 30 to 146). 
CONCLUSIONS: The majority of men were treated with αBs, mostly tamsulosin, 
and a quarter received AMs. Of AMs, the higher duration and lower  
switch and discontinuation with solifenacin possibly reflect better  
tolerability profile and adherence to treatment. However, there may be 
confounding differences in patient characteristics which could be assessed in 
future research.  
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OBJECTIVES: Advanced stage chronic kidney disease (CKD) (stages III-V) elevates 
the risk of cardiovascular mortality by 15%. Use of antihypertensives is therefore 
critical. This study estimates (1) the prevalence of advanced stage CKD in a 
representative sample of the US population, and (2) patterns of antihypertensive 
drug use in advanced stage CKD. METHODS: A retrospective cross-sectional 
analysis of 2009-2010 data from the National Health and Nutrition Examination 
Survey (NHANES) was conducted. We calculated estimated glomerular filtration 
rate (eGFR ) to classify participants as stage-III (Moderate - eGFR 30-59 
mL/min/1.73m2), stage-IV (Severe - eGFR 15-29 mL/min/1.73m2), or stage-V (Renal 
Failure -eGFR < 15 mL/min/1.73m2 ). Pregnant women and patients <18 years of 
age were excluded. Survey weights were applied to obtain national estimates. 
RESULTS: The estimated 2009-2010 prevalence of advanced stage CKD was 5.7%, 
representing 11,535,528 US adults. Of these, an estimated 10,344,775 were stage-
III (89.7%), 847,848 were stage-IV (7.4%), and 342,905 were stage-V (3.0%). The 
prevalence of advanced stage CKD was higher in females and white patients 
with a median age of 76 years. Among the advanced stage CKD population, 82.8% 
used antihypertensives. Monotherapy accounted for 24.8% of this use, while 
75.2% were on combination therapy. The most commonly used monotherapies 
were angiotensin converting enzyme inhibitors (ACE-I) (28.2%), beta blockers 
(27.5%), and diuretics (20.7%). For those on combination therapy, use of two 
diuretics (28.3%) was most common, followed by combinations of diuretic plus a 
beta-blocker (26.0%) and diuretic plus an ACE-I (23.8%). CONCLUSIONS: The 
estimated prevalence of advanced stage CKD is nearly 6% among US adults, with 
most being moderate severity. Most of these CKD patients used an 
antihypertensive, and the majority used two or more agents. Further studies are 
required to evaluate appropriateness of antihypertensive agent and associated 
cardio-protective effects.  
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OBJECTIVES: Venous thromboembolism (VTE) increases the risk of developing 
several complications, including recurrent VTE. This study quantifies the long-
term risk of complications associated with the development of an index 
recurrent VTE. METHODS: An analysis of health care insurance claims from the 
Ingenix IMPACTdatabase was conducted. Between January 2004 and September 
2008, subjects aged ≥18 years on the date of first recurrent VTE diagnosis 
requiring hospitalization (index recurrent deep vein thrombosis [DVT], 
pulmonary embolism [PE], or both) with ≥ 12 months of baseline observation 
prior to the index recurrent VTE were matched 1:1 with control VTE patients 
without recurrence, based on exact matching factors and propensity scores. The 
risk of developing thrombocytopenia, superficial venous thrombosis, venous 
ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency for 
up to 1 year after the index recurrent VTE event was compared between the 
recurrent VTE and the VTE control group. RESULTS: The recurrent VTE and VTE 
cohorts (8,001 subjects in each group) were well-matched with respect to age, 
gender, comorbidities, and VTE risk factors distributions. The absolute risks of 
developing thrombocytopenia, superficial venous thrombosis, venous ulcer, 
pulmonary hypertension, stasis dermatitis, and venous insufficiency were 7.1%, 
4.4%, 1.5%, 5.3%, 1.4%, and 7.2% for the recurrent VTE group and 2.5%, 1.3%, 0.8%, 
2.0%, 0.9%, and 3.8% for the VTE group, respectively. The corresponding risk 
ratios indicated that the risk of developing any complications was significantly 
higher for the recurrent VTE group compared to the VTE group (risk ratio [95% 
CI]: thrombocytopenia: 2.8 [2.4 - 3.3], superficial venous thrombosis: 3.3 [2.7 - 4.1], 
venous ulcer: 1.9 [1.4 - 2.6], pulmonary hypertension: 2.7 [2.2 - 3.2], stasis 
dermatitis: 1.5 [1.1 - 2.0], and venous insufficiency: 1.9 [1.6 - 2.2], all p-
values<0.01). CONCLUSIONS: In this large matched-cohort study, recurrent VTE 
patients had significantly higher risk of complications compared to VTE control 
patients.  
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